EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The combination therapy of oncolytic virotherapy

Yue Wang, Mengying Zhu, Huanyu Chi, Yang Liu, Guilin Yu

Frontiers in Pharmacology · 25.04.2024 · 15

DOI: 10.3389/fphar.2024.1380313 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 25.04.2024. Verfasst von Yue Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Compared to other cancer immunotherapies, oncolytic viruses possess several advantages, including high killing efficiency, excellent targeting capabilities, minimal adverse reactions, and multiple pathways for tumor destruction. However, the efficacy of oncolytic viruses as a monotherapy often falls short of expectations. Consequently, combining oncolytic viruses with traditional treatments to achieve synergistic effects has emerged as a promising direction for the development of oncolytic virus therapies.

Methods

This article provides a comprehensive review of the current progress in preclinical and clinical trials exploring the combination therapies involving oncolytic viruses.

Results

Specifically, we discuss the combination of oncolytic viruses with immune checkpoint inhibitors, chemotherapy, targeted therapy, and cellular therapy.

Discussion

The aim of this review is to offer valuable insights and references for the further advancement of these combination strategies in clinical applications. Further research is necessary to refine the design of combination therapies and explore novel strategies to maximize the therapeutic benefits offered by oncolytic viruses.

Schlagwörter

Stichwörter der Autor:innen

chemotherapycombined therapycytokineoncolytic virusestumor

Autor:innen und Institutionen

  • Department of General Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China.
  • Department of Clinical Integration of Traditional Chinese and Western Medicine, Liaoning University of Traditional Chinese Medicine, Shenyang, China.
  • The Second Clinical College of Dalian Medical University, Dalian, China.
  • Department of Ophthalmology, First Hospital of China Medical University, Shenyang, China.

Zitieren

APA

Wang, Y., Zhu, M., Chi, H., Liu, Y., & Yu, G. (2024). The combination therapy of oncolytic virotherapy. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1380313

Vancouver

Wang Y, Zhu M, Chi H, Liu Y, Yu G. The combination therapy of oncolytic virotherapy. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1380313

BibTeX
@article{Wang2024,
  author = {Wang, Yue and Zhu, Mengying and Chi, Huanyu and Liu, Yang and Yu, Guilin},
  title = {The combination therapy of oncolytic virotherapy},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1380313}
}
Kostenlos starten →